Global Point-of-Care Genetic Testing Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Point-of-Care Genetic Testing Market Insights, Forecast to 2034
Point-of-care genetic testing identifies variations in the genetic sequence at the bedside – enabling clinicians to react and alter therapy based upon the results.
Market Analysis and InsightsGlobal Point-of-Care Genetic Testing Market
Global Point-of-Care Genetic Testing market is expected to reach to US$ 6490.5 million in 2023, with a positive growth of %, compared with US$ 6303.8 million in 2022. Backed with the increasing demand from downstream industries, Point-of-Care Genetic Testing industry is evaluated to reach US$ 7584.5 million in 2033. The CAGR will be 2.6% during 2023 to 2033.
Globally, Point-of-Care Genetic Testing key companies include Abbott (US), Roche (Switzerland), Thermo Fisher Scientific (US), Cepheid (US), IQuum (US), Biocartis (Switzerland), Idaho Technologies (US), Optigene (UK) and Lumora (UK), etc. Abbott (US), Roche (Switzerland), Thermo Fisher Scientific (US) are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Point-of-Care Genetic Testing were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Point-of-Care Genetic Testing market and estimated to attract more attentions from industry insiders and investors.
Point-of-Care Genetic Testing can be divided into POCT Cancer Kits, Molecular POC Kits, POCT In Antibiotic Therapies and Assay Cartridge, etc. POCT Cancer Kits is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Point-of-Care Genetic Testing is widely used in various fields, such as Diagnostic Labs, Bio-Pharmaceutical Industry, Academic Institutions and Other, etc. Diagnostic Labs provides greatest supports to the Point-of-Care Genetic Testing industry development. In 2022, global % revenue of Point-of-Care Genetic Testing went into Diagnostic Labs filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Point-of-Care Genetic Testing market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Point-of-Care Genetic Testing market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
Abbott (US)
Roche (Switzerland)
Thermo Fisher Scientific (US)
Cepheid (US)
IQuum (US)
Biocartis (Switzerland)
Idaho Technologies (US)
Optigene (UK)
Lumora (UK)
Segment by Type
POCT Cancer Kits
Molecular POC Kits
POCT In Antibiotic Therapies
Assay Cartridge
Other
Diagnostic Labs
Bio-Pharmaceutical Industry
Academic Institutions
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Point-of-Care Genetic Testing introduction, etc. Point-of-Care Genetic Testing Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Point-of-Care Genetic Testing
Chapter 13Methodology and Data Sources adopted by MRAResearch
Market Analysis and InsightsGlobal Point-of-Care Genetic Testing Market
Global Point-of-Care Genetic Testing market is expected to reach to US$ 6490.5 million in 2023, with a positive growth of %, compared with US$ 6303.8 million in 2022. Backed with the increasing demand from downstream industries, Point-of-Care Genetic Testing industry is evaluated to reach US$ 7584.5 million in 2033. The CAGR will be 2.6% during 2023 to 2033.
Globally, Point-of-Care Genetic Testing key companies include Abbott (US), Roche (Switzerland), Thermo Fisher Scientific (US), Cepheid (US), IQuum (US), Biocartis (Switzerland), Idaho Technologies (US), Optigene (UK) and Lumora (UK), etc. Abbott (US), Roche (Switzerland), Thermo Fisher Scientific (US) are top 3 players and held % share in total in 2022.
When considering the consumption regions, % revenue of Point-of-Care Genetic Testing were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2023 to 2033 and the share will be % in 2033. Moreover, China, plays a key role in the whole Point-of-Care Genetic Testing market and estimated to attract more attentions from industry insiders and investors.
Point-of-Care Genetic Testing can be divided into POCT Cancer Kits, Molecular POC Kits, POCT In Antibiotic Therapies and Assay Cartridge, etc. POCT Cancer Kits is the mainstream product in the market, accounting for % revenue share globally in 2022 and the proportion will be % in 2033.
Point-of-Care Genetic Testing is widely used in various fields, such as Diagnostic Labs, Bio-Pharmaceutical Industry, Academic Institutions and Other, etc. Diagnostic Labs provides greatest supports to the Point-of-Care Genetic Testing industry development. In 2022, global % revenue of Point-of-Care Genetic Testing went into Diagnostic Labs filed and the proportion will reach to % in 2033.
Report Covers
This report presents an overview of global Point-of-Care Genetic Testing market from 2018 to 2033, aiming to help readers to get a comprehensive understanding of global Point-of-Care Genetic Testing market with multiple angles. Items like regional revenue from 2018 to 2033 and companies’ revenue and gross margin from 2018 to 2023 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2033 are also highlighted.
Companies, Type, Application and Regions Listed in the Report
By Company
Abbott (US)
Roche (Switzerland)
Thermo Fisher Scientific (US)
Cepheid (US)
IQuum (US)
Biocartis (Switzerland)
Idaho Technologies (US)
Optigene (UK)
Lumora (UK)
Segment by Type
POCT Cancer Kits
Molecular POC Kits
POCT In Antibiotic Therapies
Assay Cartridge
Other
Segment by Application
Diagnostic Labs
Bio-Pharmaceutical Industry
Academic Institutions
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2033
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2033 globally
Chapter 5Product revenue analysis by application from 2018 to 2033 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2033 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2033
Chapter 7Product revenue analysis by type and application from 2018 to 2033 in Europe. Product revenue analysis of each country in Europe from 2018 to 2033
Chapter 8Product revenue analysis by type and application from 2018 to 2033 in China. Product revenue analysis of China from 2018 to 2033
Chapter 9Product revenue analysis by type and application from 2018 to 2033 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2033
Chapter 10Product revenue analysis by type and application from 2018 to 2033 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2033.
Chapter 11Companies’ outline, covering company’s basic information, major business, Point-of-Care Genetic Testing introduction, etc. Point-of-Care Genetic Testing Revenue and Gross Margin of each company from 2018 to 2023
Chapter 12MRAResearch’s Conclusions of Point-of-Care Genetic Testing
Chapter 13Methodology and Data Sources adopted by MRAResearch